294646-77-8

中文名稱 (2R)-2-[[9-異丙基-6-[[[4-(2-吡啶基)苯基]甲基]氨基]-9H-嘌呤-2-基]氨基]-1-丁醇

英文名稱 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-(4-(2-pyridyl)benzyl)-9-isopropylpurinetrihydrochloride

CAS 294646-77-8

分子式 C24H29N7O

分子量 431.53

MOL 文件 294646-77-8.mol

更新日期 2026/06/08 14:05:54

294646-77-8 結(jié)構(gòu)式

基本信息物理化學(xué)性質(zhì) 安全數(shù)據(jù) 圖譜信息 (2R)-2-[[9-異丙基-6-[[[4-(2-吡啶基)苯基]甲基]氨基]-9H-嘌呤-2-基]氨基]-1-丁醇價格(試劑級) 常見問題列表

基本信息

中文別名

(2R)-2-[[9-異丙基-6-[[[4-(2-吡啶基)苯基]甲基]氨基]-9H-嘌呤-2-基]氨基]-1-丁醇

英文別名

R8
(S)-CR8
(R)-CR8
CR8, (R)-Isomer
CR8, (R)-Isomer - CAS 294646-77-8 - Calbiochem
(R)-2-(1-Hydroxybut-2-ylamino)-6-[4-(2-pyridyl)phenylmethylamino]-9-iso-propylpurine
2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-(4-(2-pyridyl)benzyl)-9-isopropylpurinetrihydrochloride
(2R)-2-[[9-(1-Methylethyl)-6-[[[4-(2-pyridinyl)phenyl]methyl]amino]-9H-purin-2-yl]amino]-butanol-1
(2R)-2-[[9-(1-Methylethyl)-6-[[[4-(2-pyridinyl)phenyl]methyl]amino]-9H-purin-2-yl]amino]-1-butanol
1-Butanol,2-[[9-(1-Methylethyl)-6-[[[4-(2-pyridinyl)phenyl]Methyl]aMino]-9H-purin-2-yl]aMino]-,(2R)-

物理化學(xué)性質(zhì)

熔點98-100℃

沸點671.4±65.0 °C(Predicted)

密度1.27±0.1 g/cm3(Predicted)

儲存條件2-8°C

溶解度二甲基亞砜：≥10mg/mL

酸度系數(shù)(pKa)14.56±0.10(Predicted)

形態(tài)粉末

顏色米白色

穩(wěn)定性可在-20°C下的DMSO溶液保存長達1個月。

InChIKeyHOCBJBNQIQQQGT-LJQANCHMSA-N

SMILESCC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c3ccccn3)c4ncn(C(C)C)c4n1

安全數(shù)據(jù)

危險性符號(GHS) 有害 (GHS07)

GHS07

警示詞警告

危險性描述H302-H315-H319-H335

防范說明P261-P305+P351+P338

危險品標(biāo)志Xn

危險類別碼22

WGK Germany3

存儲類別11 - Combustible Solids

圖譜信息

(2R)-2-[[9-異丙基-6-[[[4-(2-吡啶基)苯基]甲基]氨基]-9H-嘌呤-2-基]氨基]-1-丁醇(294646-77-8)核磁圖(¹HNMR)

(2R)-2-[[9-異丙基-6-[[[4-(2-吡啶基)苯基]甲基]氨基]-9H-嘌呤-2-基]氨基]-1-丁醇價格(試劑級)

報價日期	產(chǎn)品編號	產(chǎn)品名稱	CAS號	包裝	價格
2026/06/05	HY-18340	(2R)-2-[[9-異丙基-6-[[[4-(2-吡啶基)苯基]甲基]氨基]-9H-嘌呤-2-基]氨基]-1-丁醇 (R)?-?CR8	294646-77-8	5mg	2500元
2026/06/05	HY-18340	(2R)-2-[[9-異丙基-6-[[[4-(2-吡啶基)苯基]甲基]氨基]-9H-嘌呤-2-基]氨基]-1-丁醇 (R)?-?CR8	294646-77-8	10 mM * 1 mLin DMSO	2750元
2026/06/05	HY-18340	(2R)-2-[[9-異丙基-6-[[[4-(2-吡啶基)苯基]甲基]氨基]-9H-嘌呤-2-基]氨基]-1-丁醇 (R)?-?CR8	294646-77-8	10mg	4000元

常見問題列表

生物活性

(R)?-?CR8 (CR8) 是 Roscovitine 的第二代類似物，是一種有效的 CDK1/2/5/7/9 抑制劑。(R)?-?CR8 (CR8) 抑制 CDK1/cyclin B (IC50=0.09 μM)、CDK2/cyclin A (0.072 μM)、CDK2/cyclin E (0.041 μM)、CDK5/p25 (0.11 μM)、CDK7/cyclin H (1.1 μM)、CDK9/cyclin T (0.18 μM) 和 CK1δ/ε (0.4 μM)。(R)?-?CR8 (CR8) 誘導(dǎo)細(xì)胞凋亡并具有神經(jīng)保護作用。(R)?-?CR8 作為一種分子膠降解劑來消耗細(xì)胞周期蛋白 K。

靶點

Cdk1/cyclin B

0.09 μM (IC ₅₀ )

cdk2/cyclin A

0.072 μM (IC ₅₀ )

CDK2/cyclinE

0.041 μM (IC ₅₀ )

Cdk5/p25

0.11 μM (IC ₅₀ )

CDK7/cyclin H

1.1 μM (IC ₅₀ )

CDK9/Cyclin T

0.18 μM (IC ₅₀ )

CK1δ/ε

0.4 μM (IC ₅₀ )

體外研究

(R)-CR8 (CR8) (0.1-100 μM; 48 hours) is a potent inducer of apoptotic cell death with an IC ₅₀ of 0.49 μM for SH-SY5Y cell line.
(R)-CR8 (0.25-10 μM) induces a dose-dependent induction of poly-(ADP-ribose)polymerase (PARP) cleavage.
The CDK-bound form of (R)-CR8 has a solvent-exposed pyridyl moiety that induces the formation of a complex between CDK12-cyclin K and the CUL4 adaptor protein DDB1, bypassing the requirement for a substrate receptor and presenting cyclin K for ubiquitination and degradation.

Apoptosis Analysis

Cell Line:	SH-SY5Y cell line
Concentration:	0.1, 1, 10, 100 μM
Incubation Time:	24 hours
Result:	Reduced cell survival in a dose-dependent manner.

體內(nèi)研究

(R)-CR8 (5?mg/Kg; i.p.) results in a significant reduction in lesion size at 28 days in histological assessment.

Animal Model:	Adult (10 to 12 weeks old) male Sprague-Dawley rats (310 to 330?g)
Dosage:	i.p.
Administration:	5?mg/Kg
Result:	Resulted in a significant reduction in lesion size.